YOQNEAM, Israel and SAN RAMON, California, April 3 Results of an independent multi-treatment clinical study of the UltraShape(R)Contour I, the first clinically proven non-invasive solution for fatreduction and body contouring using non-thermal selective focused ultrasoundwill be presented at the American Society for Laser Medicine and Surgeryannual meeting on April 4, 2008 in Kissimmee, Florida. The presentation isentitled "Lipotripsy: Non-invasive Ultrasonic Selective Destruction ofAdipocytes using UltraShape" will take place during the scientific sessionThe Cutting Edge in Optical Diagnostics and Therapeutics of Tissues and Cells.
Hector Leal-Silva, M.D., a dermatologic surgeon based in Monterrey,Mexico, will present the results of the 36 patient clinical study using theUltraShape system on localized fat deposits in the abdomen, flanks, andthighs. The study showed definitive, measurable results in 100 percent ofpatients including an average of two-inch (5cm) reduction in circumference inthe abdomen after a series of three treatments, one month apart. CT scanstaken in a subset of study subjects showed objective quantifiable fatthickness reduction. Photographic assessment, weight and circumferentialmeasures were evaluated before and after each treatment and one month afterthe last treatment. Visual contour improvement was seen in over 85% ofpatients as assessed by an independent panel of physicians. Ninety-fourpercent (94%) of patients were satisfied with the procedure. In addition,there were no adverse events reported.
"With the major shift in patient demand toward non-invasive, pain-free,no-downtime procedures UltraShape has become a core procedure offering in myaesthetic practice," said Leal. "My clinical study demonstrated measurablecircumference reduction and visual improvement in body contour in allpatients. Moreover, my patients are happy with a high percentage of themreturning for treatment of other body areas or recommending UltraShape tofriends and family."
"Dr. Leal-Silva's impressive clinical study results combined with hissuccessful commercial experience with UltraShape further adds to our growingbody of evidence supporting UltraShape as the clinically proven non-invasiveoption for the reduction of localized fat deposits and improvement in bodycontour," said Rodger Stewart, President and Chief Executive Officer ofUltraShape Inc.
About the UltraShape(R) Contour I
The UltraShape Contour I system, based on patented focused ultrasoundtechnology, is the first scientifically and clinically proven non-invasivefat reduction and body contouring solution for both men and women. The deviceproduces mechanical, non-thermal, acoustic effects which target andselectively destroy fat cells, leaving surrounding critical structures suchas skin, blood vessels, nerves, and connective tissue intact. The UltraShapeprocedure is guided by proprietary real-time tracking and guidance technologydesigned to deliver smooth, uniform body contouring results. The softwareguarantees adherence to a pre-determined treatment algorithm minimizing riskof contour irregularities, a common side effect of liposuction. TheUltraShape procedure is performed during a convenient, "walk-in, walk-out"session carried out in an office-based environment; it requires no anesthesiaor sedation, and the vast majority of patients report no pain or discomfort.After treatment, patients immediately resume their daily routines with noneed for maintenance treatments. The UltraShape procedure is available in 50countries and over 55,000 patient treatments have been performed worldwidewith high patient satisfaction. The UltraShape Contour I received the CE Markin 2005 and a medical device license from Health Canada in 2007. TheUltraShape Contour I system is not available for sale in the United States.
UltraShape is redefining aesthetic medici